Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label Olaparib. Show all posts
Showing posts with label Olaparib. Show all posts
Saturday, May 26, 2012

see blogger's note: Medical News: More Good Data for PARP Blocker (Olaparib) in Ovarian Ca - in Meeting Coverage, ASCO from MedPage Today

›
Blogger's Note : see blog postings 'olaparib' (searchable) of March 27th and March 8th and others; also use NEJM search for mor...
Tuesday, March 27, 2012

March 27th: Medscape article - Olaparib for Ovarian Cancer, No Longer in Development

›
Olaparib for Ovarian Cancer, No Longer in Development

(2nd item) New Data Updating Overall Survival Rate in Olaparib Study -- SGO conference

›
New Data Updating Overall Survival Rate in Olaparib Study -- AUSTIN, Texas, March 27, 2012 /PRNewswire-USNewswire/ --SGO conference

Medical News:Data Confirm PARP Inhibitor (Olaparib) Slows Ovarian Ca - in Meeting Coverage, SGO from MedPage Today

›
Medical News:Data Confirm PARP Inhibitor Slows Ovarian Ca - in Meeting Coverage, SGO from MedPage Today Action Points ...
Thursday, March 15, 2012

abstract: Evaluation of Iniparib as a PARP Inhibitor (BRCA2....)

›
Evaluation of Iniparib as a PARP Inhibitor : Purpose: Poly(ADP-ribose) polymerase (PARP) inhibitors are undergoing extensive clinical te...
Thursday, March 08, 2012

March 7th /text and/or podcast: PARP Inhibitors and the Challenges of Developing Ovarian Cancer Therapeutics - Cancer Network Dr's Ledermann/Birrer

›
Blogger's Note: podcast and/or text available, registration required (free)                           ~~~~~~~~~~~~~~~~~~ PARP Inhibi...

open access: Nature Reviews: Key Advances in Medicine - Ovarian Cancer/Markman page 15-16

›
Key Advances in Medicine (book) Nature Reviews Clinical Oncology  (page 15)S11 ovarian cancer | Mutations and non-inferiority analyses s...
Saturday, January 28, 2012

Comparing Poly (ADP–Ribose) Polymerase Inhibitors With Standard Chemotherapy in BRCA-Mutated, Recurrent Ovarian Cancer: Lessons Learned From a Negative Trial (Olaparib)

›
"...Thus, although the study by Kaye et al 11 does not show a clear advantage of olaparib compared with PLD, it is noteworthy for w...
Wednesday, December 28, 2011

AstraZeneca - AstraZeneca updates on olaparib

›
AstraZeneca updates on olaparib "AstraZeneca today (December 20th, 2011) announced that its investigational compound olaparib will n...
Monday, August 22, 2011

abstract: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study : The Lancet Oncology (with/without brca mutation/s)

›
The Lancet Oncology, Early Online Publication, 22 August 2011 doi:10.1016/S1470-2045(11)70214-5 Cite or Link Using DOI Olapa...
Friday, May 20, 2011

May 20th Medscape - PARP Inhibitor Improves Outcomes in Ovarian Cancer - olaparib

›
Friday, September 17, 2010

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats - Full Text View - ClinicalTrials.gov

›
Monday, July 12, 2010

Cancer drug olaparib (PARP inhibitor) shows early promise | Philadelphia Inquirer (BRCA 1/2)

›
Thursday, June 10, 2010

ASCO: Drug May Reactivate Chemo Effect in Ovarian CA - Olaparib (PARP)

›
"Chemotherapy resulted in an overall response rate of 42% in this heavily pretreated patient population, including a 55% response rate ...